Prime Medicine: The Word Processor

Discovery Not Recovery

Disclaimer: This will be a "best ideas only" bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

This is Part 3 of an ongoing series on biotech bubble proxies — names with the platform architecture, peak valuation history, and clinical de-risking profile to become generational multi-baggers when the next biotech cycle arrives. For Part 1, please refer to my piece on AbCellera. For Part 2, please refer to my piece on Sana Biotechnology.

Every few years the gene editing story gets told again, with better tools and higher expectations. The market prices the newest version to infinity, the clinical data arrives on a timeline inconsistent with those expectations, and the correction is brutal and indiscriminate. The companies that survive the correction with their science intact and their mechanisms validated are not the ones that get re-rated, they are the ones that get re-discovered. The distinction matters because discovery feels different from recovery. Recovery is a BIG grind but discovery is a re-rating.

Prime Medicine (NASDAQ: PRME) is not the gene editing story the market told in 2020. It is a more precise version of that story, built on a more sophisticated mechanism, founded by the scientist who understood the limitations of the earlier tools better than anyone else alive and spent years building something that addresses them. I am not buying it today, and I will explain precisely why. However, I am watching it closely enough that it warrants the full treatment, because the setup has a shape I recognize.